Geneva Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$1.64M Sell
19,937
-305
-2% -$24.9K 0.03% 266
2017
Q1
$1.7M Sell
20,242
-154
-0.8% -$12.3K 0.03% 244
2016
Q4
$1.5M Sell
20,396
-770
-4% -$57.3K 0.03% 260
2016
Q3
$1.7M Buy
21,166
+1,504
+8% +$120K 0.03% 225
2016
Q2
$1.55M Buy
19,662
+177
+0.9% +$13.3K 0.03% 232
2016
Q1
$1.4M Sell
19,485
-1,397
-7% -$106K 0.03% 240
2015
Q4
$1.76M Sell
20,882
-48
-0.2% -$3.98K 0.03% 214
2015
Q3
$1.75M Buy
20,930
+1,170
+6% +$98.8K 0.04% 220
2015
Q2
$1.65M Sell
19,760
-639
-3% -$48.7K 0.03% 231
2015
Q1
$1.48M Buy
20,399
+1,655
+9% +$118K 0.03% 240
2014
Q4
$1.29M Buy
18,744
+790
+4% +$53.3K 0.02% 254
2014
Q3
$1.16M Buy
17,954
+63
+0.4% +$3.99K 0.02% 281
2014
Q2
$1.11M Buy
17,891
+254
+1% +$15.2K 0.02% 295
2014
Q1
$1.04M Buy
17,637
+608
+4% +$33.9K 0.02% 289
2013
Q4
$868K Sell
17,029
-3,298
-16% -$165K 0.02% 270
2013
Q3
$1.02M Sell
20,327
-253
-1% -$13.2K 0.02% 246
2013
Q2
$1.01M Buy
+20,580
New +$1.12M 0.02% 215

Other funds holding LLY

Geneva Advisors's LLY Position: Q2 2017 in Review

Geneva Advisors reduced its Eli Lilly (LLY) stake by 1.5% in Q2 2017, selling an estimated $24.9K and leaving 19,937 shares worth $1.64M. The position accounts for 0.03% of the portfolio, ranked #266.

Geneva Advisors first reported a position in LLY in Q2 2013 and has held it in 17 quarters since. The position peaked at $1.76M in Q4 2015. 1,247 funds tracked by Wall St. Rank hold LLY as of Q2 2017.

  • Geneva Advisors held 19,937 shares of Eli Lilly worth $1.64M as of Q2 2017.
  • Geneva Advisors sold 305 Eli Lilly shares in Q2 2017, an estimated $24.9K.
  • Eli Lilly made up 0.03% of Geneva Advisors's portfolio in Q2 2017, its #266 holding.
  • Geneva Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 17 quarters since.
  • Geneva Advisors's Eli Lilly position peaked at $1.76M in Q4 2015.
  • 1,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.